Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 20,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 20,000 shares of Biodesix stock in a transaction that occurred on Monday, January 26th. The stock was bought at an average cost of $11.80 per share, for a total transaction of $236,000.00. Following the purchase, the director owned 1,563,210 shares in the company, valued at $18,445,878. This represents a 1.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Trading Up 10.2%

Biodesix stock traded up $1.03 during trading on Tuesday, hitting $11.12. The company’s stock had a trading volume of 67,524 shares, compared to its average volume of 4,904,886. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $88.48 million, a price-to-earnings ratio of -2.00 and a beta of 0.60. The stock’s fifty day moving average is $7.67 and its 200 day moving average is $7.69. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $21.60.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.60) by $0.44. The firm had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. As a group, equities research analysts predict that Biodesix, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on BDSX. Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in Biodesix during the 3rd quarter valued at about $113,000. XTX Topco Ltd lifted its holdings in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the period. Aberdeen Group plc bought a new position in Biodesix in the fourth quarter valued at approximately $1,784,000. Finally, Oracle Investment Management Inc. acquired a new stake in Biodesix during the 3rd quarter worth $113,000. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.